The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target ...

Baird analyst Joel Beatty last night initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy ...

The decision comes amid the rising GBS cases in Pune and Pimpri Chinchwad, where patients are increasingly requiring ventilator care.

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS").

Congenital myasthenic syndromes (CMSs) are a heterogeneous group of disorders that affect the safety margin of neuromuscular transmission — the depolarization that is required for propagation of ...